Welcome to our dedicated page for Bausch + Lomb Corporation SEC filings (Ticker: BLCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bausch + Lomb Corporation filings document the reporting obligations of a Canada-incorporated eye health company whose common shares trade on the New York Stock Exchange and Toronto Stock Exchange under BLCO. Its 8-K reports cover quarterly and annual operating results, non-GAAP financial measures, guidance, investor presentations, material credit-agreement amendments and refinancing activity.
Proxy materials describe annual shareholder meeting matters, board composition, director independence, committee assignments and executive compensation governance. Other event filings record board appointments, committee changes, registered common-share details and Regulation FD disclosures tied to the company's product pipeline, Pharmaceuticals, Surgical and Vision Care operations.
Bausch & Lomb Corp reported that director Steven H. Collis acquired 5,255 common shares through an annual grant of restricted share units (RSUs) for non-employee directors. The RSUs were granted at no cash cost and are scheduled to vest immediately before the company’s next annual shareholder meeting.
Bausch & Lomb Corp director Alfonso Eduardo reported acquiring 5,255 common shares through an annual grant of restricted share units under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, as amended and restated.
The RSUs will be settled in common shares and are scheduled to vest immediately prior to the next annual meeting of shareholders.
Bausch & Lomb Corp director Russel C. Robertson acquired 1,451 restricted share units on common shares through a grant. The award was valued at $17.65 per share and increased his directly held position to 68,007 common shares, aligning his compensation partly with shareholder value.
Bausch & Lomb Corp director John Paulson received an equity grant of 1,239 restricted share units on common shares at a reference price of $17.65 per share. These units each represent a contingent right to receive one common share with no par value.
Following this grant, Paulson directly holds 72,606 common shares of Bausch & Lomb Corp. This transaction is reported as a grant, award, or other acquisition rather than an open-market purchase.
Bausch & Lomb Corp executive Frederick Munsch, SVP, Controller and CAO, reported acquiring 12,498 common shares at a price of $0.00 per share. These shares relate to performance stock units granted on March 1, 2023 that satisfied performance conditions as of February 18, 2026.
The earned PSUs will vest on March 1, 2026, generally contingent on Munsch’s continued employment through that date. Following this award, his directly held stake increased to 90,231 common shares.
Bonnefoy Luc reported acquisition or exercise transactions in this Form 4 filing.
Bausch & Lomb Corp President, Surgical, Luc Bonnefoy reported an equity award involving 10,202 common shares of the company. These shares relate to performance stock units granted on March 1, 2023 that met their performance conditions as of February 18, 2026. The earned units are scheduled to vest on March 1, 2026, generally conditioned on his continued employment, bringing his reported direct holdings to 87,564 common shares.
Bausch & Lomb Corp EVP of R&D and CMO Yehia Hashad reported an equity award acquisition. He earned 29,406 common shares underlying performance stock units originally granted on March 1, 2023 after the award satisfied its performance conditions as of February 18, 2026.
The earned PSUs will convert into common shares and vest on March 1, 2026, generally contingent on his continued employment through that date. Following this award, Hashad’s direct holdings total 163,860 common shares, aligning his compensation more closely with the company’s long-term performance.
Bausch & Lomb Corp EVP and CFO Sam Eldessouky reported an equity award tied to performance. He acquired 70,578 common shares underlying performance stock units that met performance conditions as of February 18, 2026, from a grant originally made on March 1, 2023.
The earned performance stock units will vest on March 1, 2026, generally contingent on his continued employment through that date. Following this non-cash grant/award acquisition, his directly owned common shares total 391,394.
Bausch + Lomb reports 2025 total revenue of $5,101 million, up from $4,791 million in 2024 and $4,146 million in 2023, reflecting steady growth across its global eye health portfolio.
Vision Care generated $2,923 million, or 57% of revenue, Pharmaceuticals $1,284 million (25%) and Surgical $894 million (18%). The company sells about 400 products in roughly 100 countries and employs about 13,000 people.
Bausch + Lomb remains a majority-owned subsidiary of Bausch Health Companies Inc., which held about 88% of common shares as of February 11, 2026, and BHC continues to evaluate a potential separation of the eye health business, with no assurance it will be completed.
Bausch + Lomb reported solid growth for 2025 but remained unprofitable. Fourth-quarter revenue reached $1.405 billion, up 10% year over year, with full-year revenue of $5.101 billion, up 6%. All three segments – Vision Care, Surgical and Pharmaceuticals – grew mid- to high-single digits for the year.
Despite this, the company posted a Q4 GAAP net loss of $58 million and a full-year net loss of $360 million. Profitability looked stronger on a non-GAAP basis: Q4 adjusted EBITDA rose to $326 million and full-year adjusted EBITDA was $858 million. Management guided 2026 revenue to $5.375–$5.475 billion with $1.0–$1.05 billion in adjusted EBITDA excluding acquired IPR&D, implying continued growth and margin focus.